May 3, 2022 | Press Releases
CUPERTINO, Calif., May 03, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Apr 26, 2022 | Press Releases
Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, 2022 — Reviva Pharmaceuticals Holdings, Inc....
Mar 24, 2022 | Press Releases
CUPERTINO, Calif., March 24, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Mar 22, 2022 | Press Releases
CUPERTINO, Calif., March 22, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Mar 18, 2022 | Press Releases
– 5th Annual Neuroscience Innovation Forum – – BIO-Europe Spring® 2022 – CUPERTINO, Calif., March 18, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...
Mar 15, 2022 | Press Releases
– Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 – $29.7 Million in Cash as of December 31, 2021 – CUPERTINO, Calif., March 15, 2022 — Reviva Pharmaceuticals Holdings,...
